CSF2 and breast cancer: Another phase I clinical trial was conducted to test the safety and efficacy of HER2Bi-armed ATC in combination with interleukin 2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF) in 23 patients with stage IV breast cancer.